ChemoCentryx, Inc. (CCXI) Wednesday reported a net loss of $9.7 million, or $0.28 per share for the fourth quarter, compared to earnings of $18.2 million, or $0.61 per share during the same quarter in 2011. The results reflected depressed revenues and higher operating expenses.
Meanwhile, revenues for quarter fell sharply to $2.14 million from $26.04 million for the same period in 2011. The decrease in revenues reflected a $25 million option fee recognized in 2011 resulting from GSK's election to exercise its option to license the company's product, said ChemoCentryx.
On average, four analysts polled by Thomson Reuters expected the company to report a loss of $0.28 per share on revenue of $1.21 million for the quarter. Analysts' estimates typically exclude special items.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.